Scottish microbiome biotech EnteroBiotix has reported positive early Phase II trial results for its leading gut microbiome based treatment for irritable bowel syndrome (IBS), particularly in individuals with predominant constipation symptoms.

The company’s flagship candidate EBX-102-02, is a full-spectrum microbiome product designed to replicate the complete composition of a healthy gut microbiome rather than focusing solely on a select few beneficial bacterial strains.

The study involved 122 patients with moderate to severe IBS-C (constipation-predominant) and IBS-D (diarrhea-predominant). Topline results released this week indicate significant improvements in 62 IBS-C patients based on the IBS Symptom Severity Score which evaluates stool consistency average weekly complete bowel movements and abdominal pain.

These topline results demonstrate that our full-spectrum microbiome based drug could be a breakthrough in IBS treatment said James McIlroy, CEO of EnteroBiotix in a press statement. The data validate our approach and bring us closer to providing a much-needed solution for patients with limited treatment options.

The company also stated that it expects to release final data including findings from the IBS-D cohort in Q3 2025.

Founded in 2017 by James McIlroy during his medical studies EnteroBiotix operates offices and laboratories in Glasgow and Aberdeen. McIlroy was inspired by early research indicating that if properly harnessed, the gut microbiome could be used to treat a variety of diseases.

The company has developed an innovative stabilization technology for anaerobic microbes enabling ambient temperature stability while preserving high microbial diversity in its treatments. This technology also allows for the therapies to be delivered in an easy-to-administer oral capsule enhancing patient convenience.

EBX-102-02 is EnteroBiotix’s lead candidate but the company is also developing a therapy for liver cirrhosis which demonstrated promising Phase Ib results by improving gut barrier function and reducing inflammation in participants. Additionally it is working on a treatment for patients undergoing allogeneic hematopoietic stem cell transplantation in collaboration with Imperial College London.

In the ongoing Phase IIa trial patients were randomized to receive either eight capsules of EBX-102-02 on days 1 and 7 or a placebo on the same schedule. They were then monitored for six weeks.

Patients who received EBX-102-02 began showing improvements as early as one week after treatment, with these benefits sustained throughout the follow-up period. Reported adverse events were mostly mild and self-limiting, with no serious adverse events observed.Phase IIa results suggest EBX-102-02 could be a well-tolerated first-in-class therapy for this unmet medical need.

Source: https://www.enterobiotix.com/news/enterobiotix-announces-positive-topline-phase-2a-results-with-ebx-102-02